![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/11/2912121/0/en/Oncternal-Therapeutics-to-Present-in-JonesTrading-Healthcare-Summit.html
https://www.globenewswire.com/news-release/2024/05/30/2891126/0/en/Oncternal-Announces-Enrollment-Completed-and-Dosing-Initiated-for-Fifth-Dose-Cohort-of-Phase-1-2-Study-of-ONCT-534-for-the-Treatment-of-R-R-Metastatic-Castration-Resistant-Prostate.html
https://www.globenewswire.com/news-release/2024/05/09/2879119/0/en/Oncternal-Therapeutics-Provides-Business-Update-and-Announces-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/05/02/2874670/0/en/Oncternal-Therapeutics-to-Provide-Business-Update-and-Report-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/05/01/2873281/0/en/Oncternal-Therapeutics-Reports-Inducement-Award-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/04/18/2865429/0/en/Oncternal-Announces-First-Patient-Dosed-in-Fourth-Cohort-of-Phase-1-2-Study-of-ONCT-534-for-the-Treatment-of-R-R-Metastatic-Castration-Resistant-Prostate-Cancer.html
https://www.globenewswire.com//news-release/2024/03/15/2847056/0/en/Oncternal-Participating-in-Virtual-Fireside-Chat-with-Key-Opinion-Leader-on-Treatment-Landscape-New-Treatment-Options-for-Prostate-Cancer.html
https://www.globenewswire.com//news-release/2024/03/07/2842710/0/en/Oncternal-Therapeutics-Provides-Business-Update-and-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/02/29/2838399/0/en/Oncternal-Therapeutics-to-Provide-Business-Update-and-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/02/06/2824764/0/en/Oncternal-Therapeutics-to-Participate-in-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html